Cost comparison of surgery vs organ preservation for laryngeal cancer.
OBJECTIVE
To perform a cost minimization analysis of total laryngectomy with postoperative radiotherapy vs induction chemotherapy with subsequent radiotherapy in patients with advanced (stage III or IV) squamous cell carcinoma of the larynx.


METHODS
Decision-analysis model using data from peer-reviewed trials, case series, meta-analyses, and Medicare diagnosis related group reimbursement rates.


METHODS
A hypothetical cohort of patients with stage III or IV laryngeal cancer. The perspective is that of a health care payer.


METHODS
The hypothetical patient cohort could receive (1) surgery (total laryngectomy) with postoperative radiotherapy or (2) induction chemotherapy (fluorouracil and cisplatin) with radiotherapy followed by salvage surgery for patients failing to respond to chemotherapy.


METHODS
Overall difference in direct medical costs in 2003 US dollars between the 2 treatment arms from initiation to completion of treatment.


RESULTS
In the baseline analysis, the direct medical costs for the surgical arm were 30,138 US dollars per patient. For the organ preservation arm, the direct medical costs were 33,052 US dollars per patient. The finding that the surgical arm costs were lower was robust to all sensitivity analyses except for the extreme low estimate for the cost of chemotherapy.


CONCLUSIONS
Our results suggest that total laryngectomy with postoperative radiotherapy costs nearly 3000 US dollars less than organ preservation treatment for advanced laryngeal cancer. Given that survival appears equivalent between the 2 modalities, cost consideration and patient preference may be important factors in decision making for the treatment of advanced laryngeal cancer.
Davis
Greg E
GE
Department of Otolaryngology--Head and Neck Surgery, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA 98195, USA. gedavis@u.washington.edu
Schwartz
Seth R
SR
Veenstra
David L
DL
Yueh
Bevan
B
D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000191:economics / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant / Q000191:economics*; D002945:Cisplatin / Q000191:economics / Q000627:therapeutic use; D003365:Costs and Cost Analysis; D003661:Decision Support Techniques; D005472:Fluorouracil / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D007822:Laryngeal Neoplasms / Q000191:economics / Q000473:pathology / Q000628:therapy*; D007825:Laryngectomy / Q000191:economics*; D008962:Models, Theoretical; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant / Q000191:economics*
D000970:Antineoplastic Agents; D002945:Cisplatin; D005472:Fluorouracil